HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
8- (4- ((2- aminoethyl)aminocarbonylmethyloxy)phenyl)- 1,3- dipropylxanthine
adenosine receptor antagonist
Also Known As:
8-(4-(((2-(4-aminophenylacetylamino)ethyl)carbonyl)methyl)oxy)phenyl-1,3-dipropylxanthine; 8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine, 3H-labeled; PAPAXAC; xanthine amine congener XAC
Networked:
4
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
Alkaloids: 5398
Xanthines: 123
8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine: 4
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Purines: 651
Purinones: 2
Xanthines: 123
8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine: 4
Related Diseases
1.
Ischemia
06/01/1995 - "
In this study, 2 h of ischemia and 2 h of reperfusion of the left lower lobe in intact-chest, spontaneously breathing cats caused lung injury characterized by the presence of neutrophils, macrophages, and RBCs in alveoli and caused alveolar edema, which was blocked in a highly significant manner by the A1 receptor antagonists xanthine amine congener (XAC) and 1,3-dipropyl-8-cyclopentylxanthine (DPCPX).
"
08/01/1992 - "
Adenosine, the adenosine A1-selective agonist 2-chloro-N6-cyclopentyladenosine (CCPA), the A2-selective agonist CGS 21,680, the non-selective adenosine receptor antagonist xanthine amine congener (XAC), and the adenosine uptake blocker S-(p-nitrobenzyl)-6-thioinosine (NBTI) were infused via jugular vein starting 15 min prior to release of ischemia until 0.5 h after reperfusion.
"
11/01/1996 - "
The selective A1 adenosine receptor antagonists xanthine amine congener (XAC; 0.1 mg.kg-1.h-1), bamifylline (BAM; 10 mg.kg-1.h-1), 1,3-dipropyl-8-cyclopentylxanthine (DPCPX; 10 micrograms.kg-1.min-1) administered as continous intravenous infusions for 1 hour before ischemia [DPCPX (I)], or DPCPX 30 micrograms.kg-1.min-1 administered intravenously during 30 minutes of ischemia and 30 minutes of reperfusion [DPCPX (I/R)] significantly (P < .05) reduced AN/AR from 52.2 +/- 3.8% (control, n = 5) to 23.4 +/- 6.6% (XAC, n = 5), 34.9 +/- 3.6% (BAM, n = 5), 15.9 +/- 2.9% [DPCPX(I), n = 5], or 13 +/- 3.2% [DPCPX (I/R), n = 5].
"
2.
Lung Injury
06/01/1995 - "
In this study, 2 h of ischemia and 2 h of reperfusion of the left lower lobe in intact-chest, spontaneously breathing cats caused lung injury characterized by the presence of neutrophils, macrophages, and RBCs in alveoli and caused alveolar edema, which was blocked in a highly significant manner by the A1 receptor antagonists xanthine amine congener (XAC) and 1,3-dipropyl-8-cyclopentylxanthine (DPCPX).
"
3.
Edema (Dropsy)
06/01/1995 - "
In this study, 2 h of ischemia and 2 h of reperfusion of the left lower lobe in intact-chest, spontaneously breathing cats caused lung injury characterized by the presence of neutrophils, macrophages, and RBCs in alveoli and caused alveolar edema, which was blocked in a highly significant manner by the A1 receptor antagonists xanthine amine congener (XAC) and 1,3-dipropyl-8-cyclopentylxanthine (DPCPX).
"
4.
Bradycardia
08/01/1991 - "
Pretreatment with an A1-selective antagonist xanthine amine congener (XAC, 5 pmol icv or 1 mg/kg iv) had no effect on the depressor response but antagonized the bradycardia.
"
Related Drugs and Biologics
1.
1,3-dipropyl-8-cyclopentylxanthine
2.
Purinergic P1 Receptor Antagonists
3.
Adenosine (Adenocard)
4.
bamifylline
5.
4-nitrobenzylthioinosine
Related Therapies and Procedures
1.
Intravenous Infusions